121 related articles for article (PubMed ID: 11401845)
1. Moderation of skeletal muscle reperfusion injury by a sLe(x)-glycosylated complement inhibitory protein.
Kyriakides C; Wang Y; Austen WG; Favuzza J; Kobzik L; Moore FD; Hechtman HB
Am J Physiol Cell Physiol; 2001 Jul; 281(1):C224-30. PubMed ID: 11401845
[TBL] [Abstract][Full Text] [Related]
2. Sialyl Lewis(x) hybridized complement receptor type 1 moderates acid aspiration injury.
Kyriakides C; Wang Y; Austen WG; Favuzza J; Kobzik L; Moore FD; Hechtman HB
Am J Physiol Lung Cell Mol Physiol; 2001 Dec; 281(6):L1494-9. PubMed ID: 11704546
[TBL] [Abstract][Full Text] [Related]
3. sCR1sLe ameliorates ischemia/reperfusion injury in experimental lung transplantation.
Stammberger U; Hamacher J; Hillinger S; Schmid RA
J Thorac Cardiovasc Surg; 2000 Dec; 120(6):1078-84. PubMed ID: 11088029
[TBL] [Abstract][Full Text] [Related]
4. Characterization of N-linked oligosaccharides bearing sialyl lewis x moieties on an alternatively glycosylated form of soluble complement receptor type 1 (sCR1).
Picard MD; Pettey CL; Marsh HC; Thomas LJ
Biotechnol Appl Biochem; 2000 Feb; 31(1):5-13. PubMed ID: 10669397
[TBL] [Abstract][Full Text] [Related]
5. Reduction of myocardial infarct size with sCR1sLe(x), an alternatively glycosylated form of human soluble complement receptor type 1 (sCR1), possessing sialyl Lewis x.
Zacharowski K; Otto M; Hafner G; Marsh HC; Thiemermann C
Br J Pharmacol; 1999 Nov; 128(5):945-52. PubMed ID: 10556930
[TBL] [Abstract][Full Text] [Related]
6. Production of a complement inhibitor possessing sialyl Lewis X moieties by in vitro glycosylation technology.
Thomas LJ; Panneerselvam K; Beattie DT; Picard MD; Xu B; Rittershaus CW; Marsh HC; Hammond RA; Qian J; Stevenson T; Zopf D; Bayer RJ
Glycobiology; 2004 Oct; 14(10):883-93. PubMed ID: 15190008
[TBL] [Abstract][Full Text] [Related]
7. Complement inhibition by soluble complement receptor type 1 improves microcirculation after rat liver transplantation.
Lehmann TG; Koeppel TA; Kirschfink M; Gebhard MM; Herfarth C; Otto G; Post S
Transplantation; 1998 Sep; 66(6):717-22. PubMed ID: 9771834
[TBL] [Abstract][Full Text] [Related]
8. Microvascular effects of complement blockade with soluble recombinant CR1 on ischemia/reperfusion injury of skeletal muscle.
Pemberton M; Anderson G; Vĕtvicka V; Justus DE; Ross GD
J Immunol; 1993 Jun; 150(11):5104-13. PubMed ID: 8496606
[TBL] [Abstract][Full Text] [Related]
9. Endothelial targeting and enhanced antiinflammatory effects of complement inhibitors possessing sialyl Lewisx moieties.
Mulligan MS; Warner RL; Rittershaus CW; Thomas LJ; Ryan US; Foreman KE; Crouch LD; Till GO; Ward PA
J Immunol; 1999 Apr; 162(8):4952-9. PubMed ID: 10202042
[TBL] [Abstract][Full Text] [Related]
10. Neutrophil mediated remote organ injury after lower torso ischemia and reperfusion is selectin and complement dependent.
Kyriakides C; Austen WG; Wang Y; Favuzza J; Moore FD; Hechtman HB
J Trauma; 2000 Jan; 48(1):32-8. PubMed ID: 10647562
[TBL] [Abstract][Full Text] [Related]
11. Anti-selectin therapy modifies skeletal muscle ischemia and reperfusion injury.
Weiser MR; Gibbs SA; Valeri CR; Shepro D; Hechtman HB
Shock; 1996 Jun; 5(6):402-7. PubMed ID: 8799951
[TBL] [Abstract][Full Text] [Related]
12. Blockade of complement activation prevents local and pulmonary albumin leak after lower torso ischemia-reperfusion.
Lindsay TF; Hill J; Ortiz F; Rudolph A; Valeri CR; Hechtman HB; Moore FD
Ann Surg; 1992 Dec; 216(6):677-83. PubMed ID: 1334645
[TBL] [Abstract][Full Text] [Related]
13. Skeletal muscle reperfusion injury is mediated by neutrophils and the complement membrane attack complex.
Kyriakides C; Austen W; Wang Y; Favuzza J; Kobzik L; Moore FD; Hechtman HB
Am J Physiol; 1999 Dec; 277(6):C1263-8. PubMed ID: 10600778
[TBL] [Abstract][Full Text] [Related]
14. Recombinant soluble P-selectin glycoprotein ligand 1 moderates local and remote injuries following experimental lower-torso ischaemia.
Kyriakides C; Favuzza J; Wang Y; Austen WG; Moore FD; Hechtman HB
Br J Surg; 2001 Jun; 88(6):825-30. PubMed ID: 11412252
[TBL] [Abstract][Full Text] [Related]
15. Pre-clinical evaluation of an sLe x-glycosylated complement inhibitory protein in a non-human primate model of reperfused stroke.
Ducruet AF; Mocco J; Mack WJ; Coon AL; Marsh HC; Pinsky DJ; Hickman ZL; Kim GH; Connolly ES
J Med Primatol; 2007 Dec; 36(6):375-80. PubMed ID: 17976043
[TBL] [Abstract][Full Text] [Related]
16. Neuronal protection in stroke by an sLex-glycosylated complement inhibitory protein.
Huang J; Kim LJ; Mealey R; Marsh HC; Zhang Y; Tenner AJ; Connolly ES; Pinsky DJ
Science; 1999 Jul; 285(5427):595-9. PubMed ID: 10417391
[TBL] [Abstract][Full Text] [Related]
17. sCR1sLe(X) reduces lung allograft ischemia-reperfusion injury but does not ameliorate acute rejection.
Stammberger U; Hamacher J; Pache JC; Schmid RA
Eur J Cardiothorac Surg; 2002 Sep; 22(3):368-72. PubMed ID: 12204725
[TBL] [Abstract][Full Text] [Related]
18. Soluble complement receptor type 1 inhibits the complement pathway and prevents contractile failure in the postischemic heart. Evidence that complement activation is required for neutrophil-mediated reperfusion injury.
Shandelya SM; Kuppusamy P; Herskowitz A; Weisfeldt ML; Zweier JL
Circulation; 1993 Dec; 88(6):2812-26. PubMed ID: 8252695
[TBL] [Abstract][Full Text] [Related]
19. Transgenic expression of human complement regulators reduces skeletal muscle ischaemia/reperfusion injury in mice.
Knight KR; Shinkel TA; Cowan PJ; Romeo-Meeuw R; d'Apice AJ; Morrison WA
Clin Sci (Lond); 2005 Jan; 108(1):47-53. PubMed ID: 15341509
[TBL] [Abstract][Full Text] [Related]
20. Soluble complement receptor type 1 ameliorates the local and remote organ injury after intestinal ischemia-reperfusion in the rat.
Hill J; Lindsay TF; Ortiz F; Yeh CG; Hechtman HB; Moore FD
J Immunol; 1992 Sep; 149(5):1723-8. PubMed ID: 1387151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
